The natural killer (NK) T-cell agonist IMM60 may overcome resistance to PD-1 inhibitors when combined with immunotherapy in patients with melanoma and non–small cell lung cancer (NSCLC), according to Nicholas Coupe, MBBS, PhD, who emphasized the tolerable safety profile seen so far with this combination.
2023
MRV Newsletter – October 2023
>> MRV Newsletter October 2023 (Updated: 1 November 2023, Please download again)
Read More 31-Gene Expression Profile Test Accurately Classified Risk of Death From Melanoma
Patients with the DecisionDx-Melanoma 31-gene expression profile test had a 29% lower melanoma-specific survival mortality.
Pembrolizumab Elicits Long-Term Survival Benefit in Advanced Melanoma
Pembrolizumab (Keytruda) demonstrated long-term survival benefit compared with ipilimumab (Yervoy) in patients with unresectable stage III/IV melanoma who received up to 1 prior systemic therapy, according to 7-year follow-up data from the phase 3 KEYNOTE-006 (NCT01866319) trial, which included some patients who transitioned to the phase 3 KEYNOTE-587 (NCT03486873) extension study, published in the Journal of Clinical Oncology.